Literature DB >> 2174038

Effects of cAMP-binding site mutations on intradomain cross-communication in the regulatory subunit of cAMP-dependent protein kinase I.

G E Ringheim1, S S Taylor.   

Abstract

Each protomer of the regulatory subunit dimer of cAMP-dependent protein kinase contains two tandem and homologous cAMP-binding domains, A and B, and cooperative cAMP binding to these two sites promotes holoenzyme dissociation. Several amino acid residues in the type I regulatory subunit, predicted to lie in close proximity to each bound cyclic nucleotide based on affinity labeling and model building, were replaced using recombinant techniques. The mutations included replacement of 1) Glu-200, predicted to hydrogen bond to the 2'-OH of cAMP bound to site A, with Asp, 2) Tyr-371, the site of affinity labeling with 8-N3-cAMP in site B, with Trp, and 3) Phe-247, the position in site A that is homologous to Tyr-371 in site B, with Tyr. Each mutation caused an approximate 2-fold increase in both the Ka(cAMP) and Kd(cAMP); however, the off-rates for cAMP and the characteristic pattern of affinity labeling with 8-N3-cAMP differed markedly for each mutant protein. Furthermore, these mutations affect the cAMP binding properties not only of the site containing the mutation, but of the adjacent nonmutated site as well, thus confirming that extensive cross-communication occurs between the two cAMP-binding domains. Photoaffinity labeling of the native R-subunit results in the covalent modification of two residues, Trp-260 and Tyr-371, by 8-N3-cAMP bound to sites A and B, respectively, with a stoichiometry of 1 mol of 8-N3-cAMP incorporated per mol of R-monomer (Bubis, J., and Taylor, S. S. (1987) Biochemistry 26, 3478-3486). A stoichiometry of 1 mol of 8-N3-cAMP incorporated per R-monomer was observed for each mutant regulatory subunit as well, even when 2 mol of 8-N3-cAMP were bound per R-monomer; however, the major sites of covalent modification were altered as follows: R(Y371/W), Trp-371; R(E200/D), Tyr-371, and R(F247/Y), Tyr-371.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174038

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Two PKA RIα holoenzyme states define ATP as an isoform-specific orthosteric inhibitor that competes with the allosteric activator, cAMP.

Authors:  Tsan-Wen Lu; Jian Wu; Phillip C Aoto; Jui-Hung Weng; Lalima G Ahuja; Nicholas Sun; Cecilia Y Cheng; Ping Zhang; Susan S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

Review 2.  Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.

Authors:  Zhuo Fu; Elizabeth R Gilbert; Dongmin Liu
Journal:  Curr Diabetes Rev       Date:  2013-01-01

3.  Allosteric communication between cAMP binding sites in the RI subunit of protein kinase A revealed by NMR.

Authors:  In-Ja L Byeon; Khanh K Dao; Jinwon Jung; Jeffrey Keen; Ingar Leiros; Stein O Døskeland; Aurora Martinez; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2010-03-02       Impact factor: 5.157

4.  Cloning and expression of pkaC and pkaR, the genes encoding the cAMP-dependent protein kinase of Aspergillus fumigatus.

Authors:  Brian G Oliver; John C Panepinto; Jarrod R Fortwendel; Darcey L Smith; David S Askew; Judith C Rhodes
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

5.  Ghrelin attenuates cAMP-PKA signaling to evoke insulinostatic cascade in islet β-cells.

Authors:  Katsuya Dezaki; Boldbaatar Damdindorj; Hideyuki Sone; Oleg Dyachok; Anders Tengholm; Erik Gylfe; Tomoyuki Kurashina; Masashi Yoshida; Masafumi Kakei; Toshihiko Yada
Journal:  Diabetes       Date:  2011-07-25       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.